Status:
UNKNOWN
Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy
Lead Sponsor:
Asan Medical Center
Conditions:
Polypoidal Choroidal Vasculopathy
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
1. Primary objectives a. To evaluate the Effects of intravitreal Bevacizumab on polypoidal choroidal vasculopathy(PCV) 2. Secondary objectives 1. To assess the changes in visual acuity 2. T...
Eligibility Criteria
Inclusion
- Male or female, CNV secondary to PCV
- BCVA of 20/40 to 20/320 (Snellen equivalent)
- Evidence of presumed recent disease progression (blood, growth by FA, or recent VA loss)
Exclusion
- Uncontrolled glaucoma or any other ocular condition that would prevent an improvement in visual acuity
- Media opacity in the study eye that precludes clinical and photographic evaluation
- Intraocular surgery \< 1 month before day 0
- Use of heparin/warfarin within 1 month prior to injection
- Known allergy or hypersensitivity to fluorescein, indocyanine green or povidone iodine
- Contraindication to pupil dilation in either eye
- Any condition which precludes patients' ability to comply with study requirements including completion of the study
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
End Date :
May 1 2008
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00383812
Start Date
May 1 2006
End Date
May 1 2008
Last Update
October 4 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, South Korea, 138-736